{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the CI is below the level of detection.","groupId":"OG000","lowerLimit":"3.98","upperLimit":"NA","value":"7.98"},{"comment":"The upper limit of the CI is below the level of detection.","groupId":"OG001","lowerLimit":"8.54","upperLimit":"NA","value":"16.11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Disease-specific survival refers to the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who started on placebo and crossed over to active drug after progression.\n\nAdults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG000","title":"Cohort A: Liposarcoma Crossover"},{"description":"Participants who started on placebo and crossed over to active drug after progression.\n\nAdults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG001","title":"Cohort B: Osteosarcoma Crossover"}],"paramType":"MEDIAN","populationDescription":"Participants who started on placebo and crossed over to active drug upon progression.","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Disease Specific Survival (DSS). Cohorts A and B, After Crossover.","type":"SECONDARY","unitOfMeasure":"months"}